Table 1 Baseline demographic and clinical characteristics (safety population)
From: Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies
|  | Quetiapine 300 mg/day ( n = 298) | Quetiapine 600 mg/day ( n = 307) | Placebo (n = 214) |
|---|---|---|---|
Gender,% | Â | Â | Â |
  Male | 36.9 | 39.7 | 37.4 |
  Female | 63.1 | 60.3 | 62.6 |
Age, mean (years) | 38.4 | 39.4 | 37.7 |
Weight, mean (kg) | 79.7 | 80.1 | 78.9 |
BMI, mean | 28.0 | 28.0 | 27.8 |
Symptom rating, mean total score | Â | Â | Â |
  MADRS | 27.8 | 27.5 | 28.0 |
  HAM-D | 24.2 | 24.0 | 24.2 |
  YMRS | 4.5 | 4.5 | 5.0 |
  HAM-A | 19.2 | 18.6 | 19.1 |